BCBS Arizona · Kidney Disease (CKD)

BCBS Arizona coverage for Ozempic (Kidney Disease (CKD))

Employer / Commercial Insurance

Covered with requirements

What you need to qualify

A1C of 6.5% or higher
Lab results confirming eligibility

Qualification pathways

You can qualify through any one of these.

CKD with T2DM - Initial Approval

All of:

Diagnosis of Type 2 diabetes
Chronic kidney disease (CKD) diagnosis
Goal is to reduce risk of sustained eGFR decline, end-stage kidney disease, or cardiovascular death
Age consistent with FDA labeling
Medical regimen includes standard of care for both type 2 diabetes and CKD
Does not have type 1 diabetes
No severe gastrointestinal disease (gastroparesis)
No personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2
No concomitant use of more than one GLP-1 receptor agonist or in combination with a tirzepatide-containing product
Failure, contraindication, or intolerance with THREE generic equivalents (if available) for at least three months each

Plus any one of:

A1C >= 6.5%
Fasting plasma glucose >= 126 mg/dL
2-hour plasma glucose >= 200 mg/dL during oral glucose tolerance test
Random plasma glucose >= 200 mg/dL

Documentation to bring

Completed prior authorization request form signed by prescribing provider
Chart notes documenting CKD diagnosis
Lab results confirming T2DM diagnosis (A1C, fasting plasma glucose, or OGTT values)
Documentation of failure, contraindication, or intolerance to three generic equivalent medications for at least three months each
Supporting clinical documentation confirming standard of care for type 2 diabetes and CKD is in place

Approval and renewal

Initial approval: 12 months
Renewal: every 12 months
To renew, the plan looks for improvement in A1C and Decrease in A1C from baseline; adherence to prescribed therapy regimen for diabetes including diet and exercise.

Not covered when

Severe gastrointestinal disease (gastroparesis)
Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2
Concomitant use of more than one GLP-1 receptor agonist or in combination with a tirzepatide-containing product
Type 1 diabetes

Policy note: Ozempic is specifically listed as the only agent covered for the CKD indication in this policy. This indication requires T2DM as an underlying condition. The policy states coverage is to reduce risk of sustained decline in eGFR, end-stage kidney disease, and cardiovascular death. No specific eGFR or UACR thresholds are defined in the policy; standard of care for the CKD 'other disease of concern' must be in place.

Policy effective April 1, 2026 · verified June 2, 2026 · source: Download

ACA Marketplace